Challenges translating breast cancer gene signatures into the clinic

摘要: The advent of microarray-based gene-expression profiling a decade ago raised high expectations for rapid advances in breast cancer classification, prognostication and prediction. Despite the development molecular classifications, prognostic predictive signatures, studies have not yielded definitive answers to many questions that remain germane successful implementation personalized medicine. There are lack robust signatures predict benefit from specific therapeutic agents it is still possible prognosis or chemotherapy treatment response disease subsets accurately, such as triple-negative cancer. We discuss hurdles validation classification systems, based on microarray profiling. suggest similar challenges likely be encountered translating next-generation sequencing data into clinically useful information. Finally we highlight strategies predictors future.